CAO Edward Carr sells entire 43.7K share position for $3.6M at avg $81.49, exits completely from $3.5B biotech.
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, executed 5 separate sales totaling 43,682 shares for $3,559,494.57 on 2026-03-12, reducing his holdings from 43.7K shares to zero. The sales occurred across a narrow price range ($80.71–$85.53) with a blended average of $81.49, and the timing coincides with the company's stock trading at $77.86 (3.8% below the sale prices). This complete exit by a top financial officer is noteworthy given the company's deteriorating fundamentals: annual revenue growth of -67.4%, a net loss of $-36.8M in the most recent full year, and quarterly revenue of only $396.0K, reflecting a pre-revenue or near-revenue stage biotech in financial distress. The magnitude of the sale—100% of his holdings—stands in contrast to the stock's recent 56.0% surge over 30 days and 84.8% gain over 90 days, suggesting the officer divested at elevated prices relative to the company's underlying fundamentals and burn trajectory.